X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    DAWNZERA for Hereditary Angioedema

    U.S. FDA Approves Ionis’ DAWNZERA for Hereditary Angioedema

    Major Depressive Disorder

    AbbVie to Acquire Gilgamesh Pharmaceuticals’ Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline

    FDA Approved Papzimeos

    The U.S. FDA Approved Papzimeos for RRP Treatment in Adults

    Biosimilar Ranibizumab

    Lupin, Sandoz Collab to Commercialise Biosimilar Ranibizumab

    FDA Approves Brinsupri by Insmed for Chronic Lung Condition

    FDA Approves Brinsupri by Insmed for Chronic Lung Condition

    FDA Approves Brain Tumour Treatment Modeyso by Jazz Pharma

    FDA Approves Brain Tumour Treatment Modeyso by Jazz Pharma

    Thermo Fisher New HMW Kit Powers Long Read DNA Sequencing

    Thermo Fisher New HMW Kit Powers Long-Read DNA Sequencing

    Taiwan Grants Full Approval for NEFECON IgAN Treatment

    Taiwan Grants Full Approval for NEFECON IgAN Treatment

    Agentic AI in Pharma Transforming RD to Commercialisation

    Agentic AI in Pharma: Transforming R&D to Commercialisation

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    DAWNZERA for Hereditary Angioedema

    U.S. FDA Approves Ionis’ DAWNZERA for Hereditary Angioedema

    Major Depressive Disorder

    AbbVie to Acquire Gilgamesh Pharmaceuticals’ Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline

    FDA Approved Papzimeos

    The U.S. FDA Approved Papzimeos for RRP Treatment in Adults

    Biosimilar Ranibizumab

    Lupin, Sandoz Collab to Commercialise Biosimilar Ranibizumab

    FDA Approves Brinsupri by Insmed for Chronic Lung Condition

    FDA Approves Brinsupri by Insmed for Chronic Lung Condition

    FDA Approves Brain Tumour Treatment Modeyso by Jazz Pharma

    FDA Approves Brain Tumour Treatment Modeyso by Jazz Pharma

    Thermo Fisher New HMW Kit Powers Long Read DNA Sequencing

    Thermo Fisher New HMW Kit Powers Long-Read DNA Sequencing

    Taiwan Grants Full Approval for NEFECON IgAN Treatment

    Taiwan Grants Full Approval for NEFECON IgAN Treatment

    Agentic AI in Pharma Transforming RD to Commercialisation

    Agentic AI in Pharma: Transforming R&D to Commercialisation

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result

Operationalize: Expanded Access Programs Summit West

July 29 - July 31, 2025
Clift Royal Sonesta, 495 Geary St, San Francisco, CA 94102, United States
San Francisco - USA,

Clift Royal Sonesta, 495 Geary St, San Francisco, CA 94102, United States , San Francisco, USA

The Operationalize: Expanded Access Programs Summit West – Improving Global Access to Life Changing Therapeutics
Following the successful Boston and London meetings, the Operationalize Expanded Access Programs Summit West is uniting stakeholders executing Early Access, Expanded Access and Post-Trial Access Programs to share expertise in successfully bridging the gap between innovative clinical research and patients in need.
This Summit is the only West Coast forum connecting Expanded Access teams with industry peers to share case studies in overcoming operational and regulatory challenges to streamline access to life-changing therapies! Join 60+ experts, from Eli Lilly, Gilead, Ultragenyx, Daiichi Sankyo and more for three jam-packed days in San Francisco this July. Get exclusive insights, real-world case studies and cutting-edge strategies to supercharge your Expanded Access Programs.

 

 

Event Name: Operationalize: Expanded Access Programs Summit West
Event Date: July 29 -July 31, 2025
Event Venue: Clift Royal Sonesta, 495 Geary St, San Francisco, CA 94102, United States
Event Organizers: Hanson Wade
Contact Number (with country & area code): US: +1 617 455 4188
Email: info@hansonwade.com
URL: https://ter.li/l9o5z3

Enquiry

Latest

DAWNZERA for Hereditary Angioedema
FDA Approvals

U.S. FDA Approves Ionis’ DAWNZERA for Hereditary Angioedema

28th August 2025
Manufacturing Facility in USA
Americas

Roche’s Genentech Launches New Manufacturing Facility in USA

28th August 2025
Major Depressive Disorder
Americas

AbbVie to Acquire Gilgamesh Pharmaceuticals’ Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline

27th August 2025
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In